Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endotag-1 + gemcitabine
- Development stage
- Unknown
- Lead developer
- SynCore Biotechnology
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
EndoTAG-1 + gemcitabine is a combination therapy investigated for the treatment of locally advanced and/or metastatic pancreatic adenocarcinoma. EndoTAG-1 is an investigational formulation consisting of paclitaxel encapsulated in cationic (positively charged) liposomes, which selectively targets the negatively charged endothelial cells lining newly formed tumor blood vessels. This vascular targeting disrupts tumor angiogenesis by delivering paclitaxel directly to the tumor vasculature, leading to destruction of blood vessels that supply nutrients to tumors and ultimately starving cancer cells[2][3][6]. Gemcitabine is a nucleoside analog chemotherapy agent that interferes with DNA synthesis, causing cell death in rapidly dividing cancer cells[2]. The combination aims to enhance antitumor efficacy by both disrupting tumor vasculature (via EndoTAG-1) and directly killing cancer cells (via gemcitabine). Clinical trials have shown this combination can improve outcomes in patients with advanced pancreatic cancer who are not candidates for surgery or have failed prior therapies such as FOLFIRINOX[4][5].
- Other names
- lipid-complexed paclitaxel + gemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on endotag-1 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endotag-1 + gemcitabine.